[go: up one dir, main page]

ZA936260B - Novel antibodies for conferring passive immunity against infection by a pathogen in man - Google Patents

Novel antibodies for conferring passive immunity against infection by a pathogen in man

Info

Publication number
ZA936260B
ZA936260B ZA936260A ZA936260A ZA936260B ZA 936260 B ZA936260 B ZA 936260B ZA 936260 A ZA936260 A ZA 936260A ZA 936260 A ZA936260 A ZA 936260A ZA 936260 B ZA936260 B ZA 936260B
Authority
ZA
South Africa
Prior art keywords
pathogen
man
immunity against
against infection
passive immunity
Prior art date
Application number
ZA936260A
Inventor
Mitchell Stuart Gross
Martin Rosenberg
Mark Hurle
Jerald Charles Sadoff
Steven Hoffman
Daniel R Sylvester
Yupin Charoenvit
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ZA936260B publication Critical patent/ZA936260B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205Plasmodium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA936260A 1992-09-09 1993-08-26 Novel antibodies for conferring passive immunity against infection by a pathogen in man ZA936260B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94165492A 1992-09-09 1992-09-09

Publications (1)

Publication Number Publication Date
ZA936260B true ZA936260B (en) 1994-03-18

Family

ID=25476840

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA936260A ZA936260B (en) 1992-09-09 1993-08-26 Novel antibodies for conferring passive immunity against infection by a pathogen in man

Country Status (9)

Country Link
EP (1) EP0659192A4 (en)
JP (1) JPH08500979A (en)
KR (1) KR950703573A (en)
CN (1) CN1087681A (en)
AU (1) AU4851193A (en)
CA (1) CA2143417A1 (en)
NZ (1) NZ256232A (en)
WO (1) WO1994005690A1 (en)
ZA (1) ZA936260B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009398A1 (en) * 1994-09-19 1996-03-28 Rijkslandbouwuniversiteit Wageningen Gene constructs encoding crop-protecting agents, as well as transformed plants containing and expressing such constructs, and methods of controlling plague organisms and pathogens in crops
SE9500148D0 (en) * 1995-01-18 1995-01-18 Bioinvent Internatioal Ab Antibodies for use in cancer therapy and diagnosis
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
AU2008200400B2 (en) * 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
CN1268394C (en) * 2001-01-17 2006-08-09 特鲁比昂药品公司 Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
BR0207068A (en) 2001-01-26 2004-12-21 Inhibitex Inc Clfa protein monoclonal antibody, isolated antiserum, isolated antibody and humanized antibody containing said antibody, diagnostic kit comprising said antibody, method for diagnosing an infection with s.aureus, pharmaceutical composition for treating or preventing said infection , method for inducing an immune response, method for identifying monoclonal antibodies to clfa protein and active fragment isolated from s.aureus clfa protein a
WO2004111233A1 (en) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2006106905A1 (en) * 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
TW200722518A (en) 2005-03-31 2007-06-16 Chugai Pharmaceutical Co Ltd Sc(fv)2 structural isomers
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US10307481B2 (en) 2005-07-25 2019-06-04 Aptevo Research And Development Llc CD37 immunotherapeutics and uses thereof
JP5144499B2 (en) 2006-03-31 2013-02-13 中外製薬株式会社 Antibody modification method for purifying bispecific antibodies
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
RU2487888C2 (en) 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Single-chain multivalent binding proteins with effector function
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
ES2566957T3 (en) 2007-09-26 2016-04-18 Chugai Seiyaku Kabushiki Kaisha Constant region of modified antibody
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI682995B (en) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 Antibody constant region alteration
CA2780713A1 (en) * 2009-09-03 2011-03-10 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
JP5837821B2 (en) 2009-09-24 2015-12-24 中外製薬株式会社 Antibody constant region variants
WO2011108714A1 (en) 2010-03-04 2011-09-09 中外製薬株式会社 Antibody constant region variant
PH12013500974A1 (en) 2010-11-17 2013-07-08 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
ES2732712T3 (en) 2011-10-31 2019-11-25 Chugai Pharmaceutical Co Ltd Antigen binding molecule that has a regulated conjugation between the heavy chain and the light chain
US20140271462A1 (en) 2013-03-13 2014-09-18 Imaginab, Inc. Antigen binding constructs to cd8
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
FR3025517B1 (en) 2014-09-10 2016-12-23 Repropharm LIGANDS POTENTIATING THE BIOACTIVITY OF GONADOTROPHINS
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
JP7082484B2 (en) 2015-04-01 2022-06-08 中外製薬株式会社 Method for Producing Polypeptide Heterogeneous Multimer
JP7026613B2 (en) 2015-08-07 2022-02-28 イマジナブ・インコーポレーテッド Antigen binding construct for target molecule
UA126278C2 (en) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Cd3 binding polypeptides
WO2017115773A1 (en) 2015-12-28 2017-07-06 中外製薬株式会社 Method for promoting efficiency of purification of fc region-containing polypeptide
RU2746754C2 (en) 2016-03-14 2021-04-20 Чугаи Сейяку Кабусики Кайся Cell damage inducing therapeutic medicinal product for anticancer therapy
UA126900C2 (en) 2016-04-28 2023-02-22 Чугаі Сейяку Кабусікі Кайся ANTIBODY CONTAINING DRUG
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
JPWO2019088143A1 (en) 2017-11-01 2020-11-12 中外製薬株式会社 Antibody variants and isoforms with reduced bioactivity
CN117854601B (en) * 2024-03-04 2024-05-14 鲁东大学 A method for determining complementary regions based on gene type and amino acid sequence

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632909A (en) * 1983-10-31 1986-12-30 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies which block infectivity of malarial parasites to mosquitoes
JPS63267295A (en) * 1986-12-03 1988-11-04 Sumitomo Chem Co Ltd Human antibody, antibody gene and corresponding recombinant

Also Published As

Publication number Publication date
KR950703573A (en) 1995-09-20
JPH08500979A (en) 1996-02-06
EP0659192A4 (en) 1996-09-11
EP0659192A1 (en) 1995-06-28
WO1994005690A1 (en) 1994-03-17
CA2143417A1 (en) 1994-03-17
CN1087681A (en) 1994-06-08
NZ256232A (en) 1997-02-24
AU4851193A (en) 1994-03-29

Similar Documents

Publication Publication Date Title
ZA936260B (en) Novel antibodies for conferring passive immunity against infection by a pathogen in man
AU113430S (en) A bottle
EP0497471A3 (en) A technique for improving esd immunity
GB2265221B (en) Inductive sensors
AU111329S (en) A bottle
AU111447S (en) A bottle
IL96561A0 (en) Amorphous silicon sensor
GB9205257D0 (en) A lifting device
GB9201054D0 (en) Impact sensing device
GB9206203D0 (en) Inductive sensors
GB9202926D0 (en) A reinforcement device
AU110494S (en) A bottle
GB9102059D0 (en) A vehicle suspension device
EP0465815A3 (en) Method to palletize textile packages
GB2272976B (en) A sensor
GB9121891D0 (en) A device for gripping differently sized objects
GB9025142D0 (en) Intelligent vibration sensor
GB9211116D0 (en) Inductive sensor
GB9026694D0 (en) A damping device
DK0575970T3 (en) Bag containing a concentrate
GB2296977B (en) Semi-conductor acceleration sensor
KR950022557U (en) Bag shoulder
IL127163A0 (en) A vaccine which provides protective immunity against a bacterial pathogen
CS524390A3 (en) Optoelectronic tactile sensor
BR7201652U (en) handle adaptable to different packaging